Antibodies can carry drugs that block gene reading, remove proteins, interrupt cell signals or activate immune cells. Each approach needs its own evidence that the drug reaches its target and helps people safely.
Payload diversification changes what an antibody delivers, independently of which surface antigen it binds. This map includes transcription and splicing inhibitors, repair-checkpoint inhibitors, metabolic and apoptosis agents, targeted protein degraders, immune agonists, signaling inhibitors, and additional tubulin and DNA-interacting scaffolds. Bispecific targeting is a delivery format; dual payload means distinct agents on one construct. Neither label alone establishes a new payload mechanism. Protein toxins, radionuclides, oligonucleotides, photosensitizers and antibody-directed nanocarriers have related delivery questions but retain their own format definitions. Evidence ranges from cell experiments and animal models to early clinical studies; a mechanism change does not by itself establish benefit after a TOP1 antibody-drug conjugate.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Cryptophycin payloads, Tubulysin payloads, Hemiasterlin payloads, Kinesin spindle protein inhibitor payloads.
Shares Indolinobenzodiazepine payloads, Pyridinobenzodiazepine payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Indolinobenzodiazepine payloads, Pyridinobenzodiazepine payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Immune-stimulating antibody conjugate (ISAC), Degrader-antibody conjugate (DAC), Radio-antibody & radio-ADC, Dual-payload ADC.
Shares Amanitin payloads, Transcription-inhibitor payloads, Antibody-drug conjugate (ADC).
Shares ATR inhibitor payloads, DNA damage response inhibitor payloads.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/